Toggle Main Menu Toggle Search

Open Access padlockePrints

Polymerase γ Gene POLG Determines the Risk of Sodium Valproate-Induced Liver Toxicity

Lookup NU author(s): Joanna Stewart, Professor Rita HorvathORCiD, Professor Chris Day, Professor Patrick Chinnery

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Sodium valproate (VPA) is widely used throughout the world to treat epilepsy, migraine, chronic headache, bipolar disorder, and as adjuvant chemotherapy. VPA toxicity is an uncommon but potentially fatal cause of idiosyncratic liver injury. Rare mutations in POLG, which codes for the mitochondrial DNA polymerase gamma (pol gamma), cause Alpers-Hutten-locher syndrome (AHS). AHS is a neurometabolic disorder associated with an increased risk of developing fatal VPA hepatotoxicity. We therefore set out to determine whether common genetic variants in POLG explain why some otherwise healthy individuals develop VPA hepatotoxicity. We carried out a prospective study of subjects enrolled in the Drug Induced Liver Injury Network (DILIN) from 2004 to 2008 through five US centers. POLG was sequenced and the functional consequences of VPA and novel POLG variants were evaluated in primary human cell lines and the yeast model system Saccharomyces cerevisiae. Heterozygous genetic variation in POLG was strongly associated with VPA-induced liver toxicity (odds ratio = 23.6, 95% confidence interval [CI] = 8.4-65.8, P = 5.1 x 10(-7)). This was principally due to the p.Q1236H substitution which compromised poly function in yeast. Therapeutic doses of VPA inhibited human cellular proliferation and high doses caused nonapoptotic cell death, which was not mediated through mitochondrial DNA depletion, mutation, or a defect of fatty acid metabolism. Conclusion: These findings implicate impaired liver regeneration in VPA toxicity and show that prospective genetic testing of POLG will identify individuals at high risk of this potentially fatal consequence of treatment. (HEPATOLOGY 2010;52:1791-1796)


Publication metadata

Author(s): Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, Fontana RJ, Day CP, Chinnery PF

Publication type: Article

Publication status: Published

Journal: Hepatology

Year: 2010

Volume: 52

Issue: 5

Pages: 1791-1796

Print publication date: 01/11/2010

ISSN (print): 0270-9139

ISSN (electronic): 1527-3350

Publisher: Wiley-Blackwell Publishing

URL: http://dx.doi.org/10.1002/hep.23891

DOI: 10.1002/hep.23891


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Medical Research Council (UK)
UK NIHR Biomedical Research Centre for Ageing
UK Parkinson's Disease Societys
01GM0601German Ministry of Education and Research (BMBF; Bonn, Germany)
GGP07019Telethon-Italy Foundation
HO 2505/2-1Deutsche Forschungsgemeinschaft
RES0211/7262Newcastle upon Tyne Hospitals

Share